Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: A phase II study with a 5-year follow-up
- 28 February 2005
- journal article
- clinical trial
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 23 (1) , 1-7
- https://doi.org/10.1016/j.urolonc.2004.06.003
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Novel endpoints and design of early clinical trialsAnnals of Oncology, 2002
- State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate CancerThe Oncologist, 2002
- Chemotherapy in advanced androgen-independent prostate cancer 1990–1999: A decade of progress?Annals of Oncology, 2000
- Chemotherapy for patients with advanced prostate carcinomaCancer, 2000
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 1999
- The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a reviewCancer Chemotherapy and Pharmacology, 1999
- Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate CancerJournal of Clinical Oncology, 1999
- Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate CancerAmerican Journal of Clinical Oncology, 1997
- Clinical Trials in Relapsed Prostate Cancer: Defining the TargetJNCI Journal of the National Cancer Institute, 1996
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.Journal of Clinical Oncology, 1994